依普利酮中国的价格是多少？

A new generation of selective aldosterone antagonist (eplerenone) was developed by Pfizer/Pharmacia under the trade name Inspra. It was approved for clinical use by the U.S. Food and Drug Administration in 2002. Eplerenone is suitable for 1. Congestive heart failure after acute myocardial infarction: Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction; 2. Anti-hypertension: Eplerenone can be used alone or in combination with other anti-hypertensive drugs for the treatment of hypertension.

Eplerenone medication for different patients: 1. Congestive heart failure after acute myocardial infarction: The recommended dose is 50 mg/time, once/day. The initial dose should be 25 mg/time, once/day, and within 4 weeks, the dose should be gradually increased to 50 mg/time, once/day if the patient tolerates it. 2. Anti-hypertensive: Eplerenone can be used alone or in combination with other anti-hypertensive drugs. The recommended initial dose for use alone is 50mg/time, once/day. Obvious pressure-reducing effect will appear within four weeks of taking the medicine. If the pressure effect is not obvious, it can be increased to 50mg/time, 2 times/day. Higher dosages are not recommended, otherwise there is an increased risk of adverse reactions such as hyperkalemia.

Recently, many patients have asked their medical companions what is the price of eplerenone in China?

It is understood that (eplerenone) applied for patent protection in China in 2006, but the editor of Medical Travel has reviewed relevant information and found that there is currently no news of eplerenone being launched in China, so we do not know the price of eplerenone (eplerenone) in China.